Edgewise Therapeutics announced the appointment of Marc Semigran, M.D., as Chief Development Officer. Dr. Semigran brings considerable clinical development and translational medicine experience to Edgewise, having most recently served as Chief Medical Officer at Renovacor through its acquisition by Rocket Pharmaceuticals, Inc., and previously served as CMO and Senior Vice President of medical science at MyoKardia through its acquisition by Bristol Myers Squibb in 2020 for $13.1 billion. He will be responsible for leading cardiovascular development at Edgewise. "We are thrilled to welcome Marc to the team and are eager to begin working together as we prepare to advance our novel cardiac program into clinical development," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Marc’s cardiovascular drug development expertise will be invaluable as we advance our cardiac program towards an anticipated IND filing in the second half of 2023."
Published first on TheFly
